Find and Pitch Jounalists, Get Your Story Covered

Tags: antibody therapy, B cells, drug development, immunotherapy, monoclonal antibodies Bispecific Antibodies DLBCL Therapeutic Potential

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	European Commission grants orphan drug designation for Vivet’s VTX-806 - 15 days ago
2	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Grants Regenerative Medicine Advanced Therapy Designation for OBX-115 - 16 days ago GSK5764227 Receives Breakthrough Therapy Designation to Treat Extensive-Stage Small–Cell Lung Cancer - about 1 month ago
3	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline - 22 days ago Another ADC Developer Lands a Mega Round of Financing for Cancer Clinical Trials - 5 months ago Novartis Pays $150M to Nab a Phase 3-Ready Protein Degrader for Prostate Cancer - 5 months ago
4	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	SynaptixBio awarded £2m BioMedical Catalyst grant from Innovate UK - 29 days ago
5	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	In a Duchenne market beset by problems, Capricor data marks a bright spot - about 2 months ago Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder - 2 months ago To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach - 6 months ago
6	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more - about 2 months ago
7	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies - about 2 months ago STAT+: Investors funnel $275 million into Paragon Therapeutics spinout - 6 months ago STAT+: Biotech launches with $135 million for Vertex-competing pain medicine - 7 months ago STAT+: Startup launches with $245 million for twice yearly asthma treatment - 11 months ago
8	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline - 2 months ago Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D - 6 months ago Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category - 7 months ago Behind a big-name rare disease biotech, an exec draws from personal experience - 7 months ago Astellas’ science chief on the leap into new technologies - 7 months ago Red Jacket: Helen Sabzevari, an immunotherapy pioneer - 11 months ago
9	Michael Nuñez VentureBeat Editorial Director at VentureBeat. San Francisco editorial directiontechnology news	McKesson, Merck back Atropos Health’s $33M round to accelerate drug development with AI - 4 months ago
10	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 5 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more - 8 months ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - 9 months ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - 9 months ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - 11 months ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - 11 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - 11 months ago

Journalists covering Arxx Therapeutics